|
Indications And Usage Acromegaly Sandostatin ® (Octreotide Acetate) Is Indicated To Reduce Blood Levels Of Growth Hormone And Igf-I (Somatomedin C) In Acromegaly Patients Who Have Had Inadequate Response To Or Cannot Be Treated With Surgical Resection, Pituitary Irradiation, And Bromocriptine Mesylate At Maximally Tolerated Doses. The Goal Is To Achieve Normalization Of Growth Hormone And Igf-I (Somatomedin C) Levels ( See Dosage And Administration ). In Patients With Acromegaly, Sandostatin Reduces Growth Hormone To Within Normal Ranges In 50% Of Patients And Reduces Igf-I (Somatomedin C) To Within Normal Ranges In 50%-60% Of Patients. Since The Effects Of Pituitary Irradiation May Not Become Maximal For Several Years, Adjunctive Therapy With Sandostatin To Reduce Blood Levels Of Growth Hormone And Igf-I (Somatomedin C) Offers Potential Benefit Before The Effects Of Irradiation Are Manifested. Improvement In Clinical Signs And Symptoms, Or Reduction In Tumor Size Or Rate Of Growth, Were Not Shown In Clinical Trials Performed With Sandostatin; These Trials Were Not Optimally Designed To Detect Such Effects. Carcinoid Tumors Sandostatin Is Indicated For The Symptomatic Treatment Of Patients With Metastatic Carcinoid Tumors Where It Suppresses Or Inhibits The Severe Diarrhea And Flushing Episodes Associated With The Disease. Sandostatin Studies Were Not Designed To Show An Effect On The Size, Rate Of Growth, Or Development Of Metastases. Vasoactive Intestinal Peptide Tumors (Vipomas) Sandostatin Is Indicated For The Treatment Of The Profuse Watery Diarrhea Associated With Vip-Secreting Tumors. Sandostatin Studies Were Not Designed To Show An Effect On The Size, Rate Of Growth, Or Development Of Metastases.
|